208 related articles for article (PubMed ID: 30420593)
21. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American lymphoma classification.
Arrowsmith ER; Macon WR; Kinney MC; Stein RS; Goodman SA; Morgan DS; Flexner JM; Cousar JB; Jagasia MH; McCurley TL; Greer JP
Leuk Lymphoma; 2003 Feb; 44(2):241-9. PubMed ID: 12688340
[TBL] [Abstract][Full Text] [Related]
22. Prolonged survival of patients with peripheral T-cell lymphoma after first-line intensive sequential chemotherapy with autologous stem cell transplantation.
Prochazka V; Faber E; Raida L; Vondrakova J; Kucerova L; Jarosova M; Indrak K; Papajik T
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2009 Mar; 153(1):63-6. PubMed ID: 19365529
[TBL] [Abstract][Full Text] [Related]
23. Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma.
Cho-Vega JH; Rassidakis GZ; Amin HM; Tsioli P; Spurgers K; Remache YK; Vega F; Goy AH; Gilles F; Medeiros LJ
Leukemia; 2004 Nov; 18(11):1872-8. PubMed ID: 15385932
[TBL] [Abstract][Full Text] [Related]
24. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma.
Valleron W; Ysebaert L; Berquet L; Fataccioli V; Quelen C; Martin A; Parrens M; Lamant L; de Leval L; Gisselbrecht C; Gaulard P; Brousset P
Blood; 2012 Nov; 120(19):3997-4005. PubMed ID: 22990019
[TBL] [Abstract][Full Text] [Related]
25. Clinical value of ALK and CD30 expression in mature systemic T cell lymphomas: analysis from the Czech Lymphoma Study Group database (NIHIL).
Janikova A; Michalka J; Chloupkova R; Kopalova N; Campr V; Kamaradova K; Kren L; Belada D; Benesova K; Dlouha J; Klener P; Procházka V; Mocikova H; Duras J; Trneny M
Ann Hematol; 2022 Apr; 101(4):789-798. PubMed ID: 35061088
[TBL] [Abstract][Full Text] [Related]
26. The risk of central nervous system relapses in patients with peripheral T-cell lymphoma.
Chihara D; Fanale MA; Miranda RN; Noorani M; Westin JR; Nastoupil LJ; Hagemeister FB; Fayad LE; Romaguera JE; Samaniego F; Turturro F; Lee HJ; Neelapu SS; Rodriguez MA; Wang M; Fowler NH; Davis RE; Medeiros LJ; Oki Y
PLoS One; 2018; 13(3):e0191461. PubMed ID: 29538376
[TBL] [Abstract][Full Text] [Related]
27. Differential expression of cyclin D3 in ALK+ and ALK- anaplastic large cell lymphoma.
Dalton RR; Rassidakis GZ; Atwell C; Wang S; Oyarzo MP; Medeiros LJ
Hum Pathol; 2005 Jul; 36(7):806-11. PubMed ID: 16084951
[TBL] [Abstract][Full Text] [Related]
28. Pathobiology and molecular profiling of peripheral T-cell lymphomas.
de Leval L; Gaulard P
Hematology Am Soc Hematol Educ Program; 2008; ():272-9. PubMed ID: 19074096
[TBL] [Abstract][Full Text] [Related]
29. Clinico-pathologic features and outcome of Japanese patients with peripheral T-cell lymphomas.
Niitsu N; Okamoto M; Nakamine H; Aoki S; Motomura S; Hirano M
Hematol Oncol; 2008 Sep; 26(3):152-8. PubMed ID: 18395866
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
31. Genomics of Peripheral T-Cell Lymphoma and Its Implications for Personalized Medicine.
Zhang Y; Lee D; Brimer T; Hussaini M; Sokol L
Front Oncol; 2020; 10():898. PubMed ID: 32637355
[TBL] [Abstract][Full Text] [Related]
32. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma.
Zhang Q; Raghunath PN; Xue L; Majewski M; Carpentieri DF; Odum N; Morris S; Skorski T; Wasik MA
J Immunol; 2002 Jan; 168(1):466-74. PubMed ID: 11751994
[TBL] [Abstract][Full Text] [Related]
33. Proliferative, pro-inflammatory, and angiogenesis regulator gene expression profile defines prognosis in different histopathological subtypes of nodal peripheral T-cell lymphoma.
de Pádua Covas Lage LA; Levy D; Xavier FD; Reis DC; de Oliveira Costa R; Gonçalves MC; Rocha V; Zerbini MCN; Pereira J
Oncotarget; 2019 Aug; 10(50):5136-5151. PubMed ID: 31497245
[TBL] [Abstract][Full Text] [Related]
34. The Expressions of P53, Bcl-2, and P-Glycoprotein and Prognostic Impact in Patients with Peripheral T-Cell Lymphoma (PTCL).
Julamanee J; Kayasut K; Lekhakula A
J Med Assoc Thai; 2015 Oct; 98(10):950-6. PubMed ID: 26638586
[TBL] [Abstract][Full Text] [Related]
35. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM
Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
[TBL] [Abstract][Full Text] [Related]
36. Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis.
Setsu N; Kohashi K; Endo M; Yamamoto H; Tamiya S; Takahashi Y; Yamada Y; Ishii T; Matsuda S; Yokoyama R; Iwamoto Y; Oda Y
Int J Cancer; 2013 Jan; 132(1):109-15. PubMed ID: 22644781
[TBL] [Abstract][Full Text] [Related]
37. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma.
Iqbal J; Wright G; Wang C; Rosenwald A; Gascoyne RD; Weisenburger DD; Greiner TC; Smith L; Guo S; Wilcox RA; Teh BT; Lim ST; Tan SY; Rimsza LM; Jaffe ES; Campo E; Martinez A; Delabie J; Braziel RM; Cook JR; Tubbs RR; Ott G; Geissinger E; Gaulard P; Piccaluga PP; Pileri SA; Au WY; Nakamura S; Seto M; Berger F; de Leval L; Connors JM; Armitage J; Vose J; Chan WC; Staudt LM;
Blood; 2014 May; 123(19):2915-23. PubMed ID: 24632715
[TBL] [Abstract][Full Text] [Related]
38. Alisertib (MLN8237) an investigational agent suppresses Aurora A and B activity, inhibits proliferation, promotes endo-reduplication and induces apoptosis in T-NHL cell lines supporting its importance in PTCL treatment.
Qi W; Spier C; Liu X; Agarwal A; Cooke LS; Persky DO; Chen D; Miller TP; Mahadevan D
Leuk Res; 2013 Apr; 37(4):434-9. PubMed ID: 23153524
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas.
Moskowitz AJ; Ghione P; Jacobsen E; Ruan J; Schatz JH; Noor S; Myskowski P; Vardhana S; Ganesan N; Hancock H; Davey T; Perez L; Ryu S; Santarosa A; Dowd J; Obadi O; Pomerantz L; Yi N; Sohail S; Galasso N; Neuman R; Liotta B; Blouin W; Baik J; Geyer MB; Noy A; Straus D; Kumar P; Dogan A; Hollmann T; Drill E; Rademaker J; Schoder H; Inghirami G; Weinstock DM; Horwitz SM
Blood; 2021 Dec; 138(26):2828-2837. PubMed ID: 34653242
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical expression of the p53, mdm2, p21/Waf-1, Rb, p16, Ki67, cyclin D1, cyclin A and cyclin B1 proteins and apoptotic index in T-cell lymphomas.
Kanavaros P; Bai M; Stefanaki K; Poussias G; Rontogianni D; Zioga E; Gorgoulis V; Agnantis NJ
Histol Histopathol; 2001 Apr; 16(2):377-86. PubMed ID: 11332692
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
